## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> SMITH SANDFORD D						2. Issuer Name and Ticker or Trading Symbol <u>CYTOKINETICS INC</u> [ CYTK ]									(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)		rst) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/03/2017											er (give title		Other ( below)			
280 EAS	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street) SOUTH SAN FRANCISCO CA 94080																X Form Form	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)					•																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) Date (Month/Day						Execution Date			, Transaction Disp Code (Instr. and				curities Acquired (A osed Of (D) (Instr. 3 5)			Securi Benefi Owned	ities Fo icially (D) d Ind		rect (I)	7. Nature of Indirect Beneficial Ownership	
									Co	ode	v	Amoun	t (4 (E	() or ()	Price				r. 4)	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	re Conversion Date Execution Date if any			on Date,	Code (In					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		r. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sisable	Exj	piration te	Title	or	ount nber ıres						
Non- Qualified Stock Option (right to buy)	\$12.4	01/03/2017			A		4,032		02/03/	/2017 <sup>(1)</sup>	01/	/03/2027	Commo Stock	<sup>n</sup> 4,0	)32	\$4.9603 <sup>(2)</sup>	4,032		D		

Explanation of Responses:

1. This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018.

2. This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of \$40,000.00

## By: Sharon A. Barbari For: Sandford D. Smith

01/04/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.